Pharmaceuticals

Global Specific Antiviral Drugs For COVID 19 Market Set for Strong Expansion, Reaching $33.17 Billion With 16.8% CAGR by 2030

February 18, 2026February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the specific antiviral drugs for covid 19 market from 2026–2035 with trusted insights from The Business Research Company

How much is the Specific Antiviral Drugs For COVID 19 Market valued at in 2026, and what valuation is forecast for 2030?

The market size for specific antiviral drugs addressing COVID-19 has seen considerable expansion in recent years. This market is projected to expand from $15.23 billion in 2025 to $17.83 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.1%. Factors contributing to its historical growth include the swift dissemination of COVID-19, the issuance of emergency use authorizations, a reliance on established antiviral drug categories, constrained global manufacturing capabilities, and elevated hospitalization rates.

The market size for specific antiviral drugs for covid 19 is anticipated to undergo significant expansion in the coming years, with projections indicating a rise to $33.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.8%. This expansion during the forecast period is driven by the development of next-generation antiviral drugs, increased public-private partnerships, a rise in the adoption of preventive treatments, the broadening of combination therapies, and the incorporation of personalized medicine approaches. Prominent trends within this forecast period include increasing investment in covid-19 antiviral drug development, a growing uptake of oral antiviral tablets, the advancement of monoclonal antibody therapies, the expansion of hospital and retail distribution channels, and an emphasis on targeted treatment for hospitalized and high-risk patients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Drivers Are Influencing The Growth Of The Specific Antiviral Drugs For COVID 19 Market?

The anticipated rise in COVID-19 cases is set to stimulate the growth of the specific antiviral drugs for the COVID-19 market moving forward. COVID-19 cases signify individuals who have tested positive for the SARS-CoV-2 virus, which causes the disease. This increase in COVID-19 cases can be attributed to the appearance of new variants that spread more readily and can partly bypass immunity gained from vaccines or previous infections. Specific antiviral drugs for COVID-19 are crucial for reducing the illness’s severity and duration, leading to improved patient outcomes and a decrease in the overall impact of COVID-19 cases. For example, in May 2025, the World Health Organization, a global public health agency based in Switzerland, reported that the Eastern Mediterranean region’s test positivity rate escalated from 4% to 17% in early 2025, a figure higher than the corresponding period in 2024. Thus, the escalating count of COVID-19 cases is a significant driver for the expansion of the specific antiviral drugs for the COVID-19 market.

What Segments Are Included Within The Specific Antiviral Drugs For COVID 19 Market?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

How Are Emerging Trends Affecting The Progression Of The Specific Antiviral Drugs For COVID 19 Market?

Leading companies operating within the specific antiviral drugs for the COVID-19 market are concentrating on developing innovative treatments, such as oral antiviral therapies, to improve the accessibility and effectiveness of care. Oral antiviral therapies are medications consumed by mouth to inhibit the replication of viruses like COVID-19, thereby offering a convenient and effective treatment alternative. For example, in March 2024, Shionogi And Co., a Japan-based pharmaceutical company, launched Xocova and received full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Additionally, this drug also offers post-exposure prophylaxis by significantly reducing the risk of developing symptomatic COVID-19 in exposed individuals and shortens symptom duration with a favorable safety profile.

Who Are The Core Companies Influencing Trends In The Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Regions Are Projected To Dominate The Specific Antiviral Drugs For COVID 19 Market In The Coming Years?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Specific Antiviral Drugs For COVID 19 Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

The Antiviral And Antimicrobial Coatings Market Report 2026

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795